Mutation accumulation following extended exposure of human HepaRG cells to a genotoxic carcinogen
- 22 August 2025
- journal article
- Published by Taylor & Francis in Journal of Environmental Science and Health, Part C
- Vol. 43 (4) , 333-355
Abstract
Accurately evaluating chemical risk may benefit from the development of human-relevant models capable of capturing the effects of treatments that closely mimic real-world environmental and pharmaceutical exposures. Building on our previous work (Seo et al. Arch Toxicol 98:1919-1935),1 where cytotoxicity compromised mutation detection following short-term treatments, this study investigated mutation accumulation in both 2D and 3D HepaRG cultures following 7- and 14-day exposures with relatively non-cytotoxic N-nitrosodimethylamine (NDMA) concentrations. A multi-endpoint approach was employed to assess NDMA-induced DNA damage, micronucleus formation, and mutagenesis. Seven-day NDMA treatments were not cytotoxic but produced concentration-dependent increases in DNA damage and mutations. After 14 days of exposure, the highest NDMA concentrations produced no more than 30% cytotoxicity, and induced greater mutation frequencies compared to the 7-day exposures. Overall, the mutation frequencies induced by NDMA exhibited concentration- and treatment-duration-dependent relationships in both 2D and 3D HepaRG cultures, with notably higher mutation frequencies in 3D spheroids than in 2D cultures. Quantitative analysis by benchmark concentration (BMC) modeling demonstrated lower BMC values in 3D spheroids compared to their 2D counterparts. The predominant mutation in NDMA-treated cultures was T→C transition. These findings indicate the value of extended exposure periods for conducting in vitro genotoxicity testing in HepaRG cells.Keywords
Funding Information
- National Center for Toxicological Research
- Center for Drug Evaluation and Research
- U.S. Food and Drug Administration
- Oak Ridge Institute for Science Education
This publication has 54 references indexed in Scilit:
- Benchmark Response (BMR) Values for In Vivo Mutagenicity EndpointsEnvironmental and Molecular Mutagenesis, 2025
- Genotoxicity assessment in HepaRG™ cells as a new approach methodology follow up to a positive response in the human TK6 cell micronucleus assay: Naphthalene case studyEnvironmental and Molecular Mutagenesis, 2023
- The in vitro genotoxicity potency of mixtures of pyrrolizidine alkaloids can be explained by dose addition of the individual mixture componentsEnvironmental and Molecular Mutagenesis, 2022
- Genetic toxicity testing using human in vitro organotypic airway cultures: Assessing DNA damage with the CometChip and mutagenesis by Duplex SequencingEnvironmental and Molecular Mutagenesis, 2021
- Performance of high-throughput CometChip assay using primary human hepatocytes: a comparison of DNA damage responses with in vitro human hepatoma cell linesArchives of Toxicology, 2020
- Mutation as a Toxicological Endpoint for Regulatory Decision‐MakingEnvironmental and Molecular Mutagenesis, 2019
- 3Rs friendly study designs facilitate rat liver and blood micronucleus assays and Pig‐a gene mutation assessments: Proof‐of‐concept with 13 reference chemicalsEnvironmental and Molecular Mutagenesis, 2019
- Quantitative comparison of in vitro genotoxicity between metabolically competent HepaRG cells and HepG2 cells using the high-throughput high-content CometChip assayArchives of Toxicology, 2019
- Comparison ofhprtandlacImutant frequency with DNA adduct formation inN-hydroxy-2-acetylaminofluorene-treated Big Blue® rats†Environmental and Molecular Mutagenesis, 2001
- Evaluation of the rodent micronucleus assay by a 28‐day treatment protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)–Mammalian Mutagenicity Study Group (MMS)Environmental and Molecular Mutagenesis, 2001